exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088185 RNA Name: hsa-miR-342-3p RNA Type: miRNA Chromosome: chr14 Starnd: + Coordinate: Start Site(bp): 100109715 End Site(bp): 100109737 External Links: hsa-miR-342-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand AC009133.6 chr16 29812261 29820092 + ACVR1B chr12 51951699 51997078 + CRIM1 chr2 36355778 36551135 + E2F1 chr20 33675477 33686385 - EXOSC6 chr16 70246778 70251940 - IGFBP4 chr17 40443450 40457725 + LASP1 chr17 38869859 38921770 + PAGR1 chr16 29816152 29822489 + UBTF chr17 44205033 44221626 - USP31 chr16 23061406 23149270 - WDR77 chr1 111439890 111449256 - miRNA targets: NA circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC010327.5 chr19 55216660 55221616 + AC016876.2 chr17 7581964 7584086 - AC021078.1 chr5 149494314 149504670 - AL356488.2 chr1 109100193 109100619 + CKMT2-AS1 chr5 81201341 81301565 - H19 chr11 1995176 2001470 - LINC00894 chrX 149938613 150224580 + NEAT1 chr11 65422774 65445540 + OIP5-AS1 chr15 41283990 41309737 + SNHG20 chr17 77086716 77099902 + SNHG7 chr9 136721366 136728184 - STAG3L5P-PVRIG2P-PILRB chr7 100336104 100367831 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.